Publications by authors named "Jennifer Donnell"

Claim this Profile
I
Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo.
Ian Nessler, Baron Rubahamya, Anna Kopp, Scott Hofsess, Thomas M Cardillo, Jennifer Donnell

Mol Cancer Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release.
Anna Kopp, Scott Hofsess, Thomas M Cardillo, Serengulam V Govindan, Jennifer Donnell

Mol Cancer Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
David K Williams, Jay A Markwalder, Aaron J Balog, Bin Chen, Libing Chen, Jennifer Donnell

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130).
Robert M Sharkey, Serengulam V Govindan, Thomas M Cardillo, Jennifer Donnell, Jing Xia

Mol Cancer Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis